Fig. 8
From: Development of an efficient NUPR1 inhibitor with anticancer activity
Antitumoral effect induced by LZX-2-73 treatment in vivo. Results on Crl:NU(Ico)-Foxn1nu mice bearing pancreatic cancer MIA PaCa-2 cell lines xenograft treated daily with the vehicle or 5 or 25 mg/kg LZX-2-73 via intraperitoneal injection (n = 3). Tumor volume and mice body weight were measured twice per week. **p < 0.01 (1-way ANOVA, Dunnett’s test).
